



Dear Customer:

As you may know, FLOVENT[®] ROTADISK[®] (fluticasone propionate inhalation powder) is being phased out from the US marketplace. GlaxoSmithKline intends to cease manufacture of FLOVENT ROTADISK at the end of August 2004. GSK will continue to supply product until existing inventory of each strength of FLOVENT ROTADISK has been exhausted.

The table below lists the 3 strengths of FLOVENT ROTADISK and the corresponding NDC codes scheduled to be discontinued.

NDC	Product Description
0173-0511-00	FLOVENT ROTADISK 50 mcg
0173-0509-00	FLOVENT ROTADISK 100 mcg
0173-0504-00	FLOVENT ROTADISK 250 mcg

Please note that this phaseout applies only to the ROTADISK formulation. Other fluticasone propionate-containing products, such as FLOVENT[®] (fluticasone propionate) Inhalation Aerosol 44 mcg, 110 mcg, and 220 mcg, will continue to be supplied to the US market.

For questions pertaining to the phaseout of FLOVENT ROTADISK, please call GlaxoSmithKline at 1-800-340-3236. If you have questions concerning your order, please contact Customer Relations at 1-800-877-1158.

Sincerely,

John L. Fish
Vice President
Trade, Pharmacy Sales & Operations

Important Information:

FLOVENT is NOT indicated for the relief of acute bronchospasm.

Adrenal insufficiency may occur when transferring patients from systemic steroids to inhaled corticosteroids (see WARNINGS in complete Prescribing Information).

FLOVENT ROTADISK is indicated for the maintenance treatment of asthma as prophylactic therapy in patients 4 years of age and older. It is also indicated for patients requiring oral corticosteroid therapy for asthma. Many of these patients may be able to reduce or eliminate their requirement for oral corticosteroids over time.

FLOVENT Inhalation Aerosol is indicated for the maintenance treatment of asthma as prophylactic therapy in patients 12 years of age and older. It is also indicated for patients requiring oral corticosteroid therapy for asthma. Many of these patients may be able to reduce or eliminate their requirement for oral corticosteroids over time.

Please consult accompanying complete Prescribing Information.